A parent’s score on the electronic Psychosocial Assessment Tool following the diagnosis of cancer in a child was predictive of future levels of parental distress, according to the results of a new study.
A study exploring the genetic underpinnings of the newly classified high-grade neuroendocrine carcinoma has found that it is a rare but aggressive tumor with a high frequency of BRAF mutations.
About one in every 25 patients with chronic lymphocytic leukemia had abnormal liver function tests, and one in four developed liver dysfunction within 10 years, according to the results of a retrospective study.
The off-label use of the beta-blocker propranolol significantly reduced disease recurrence among patients with non-metastatic melanoma, according to the results of a prospective, non-randomized study.
From 1989 to 2015, breast cancer death rates decreased by 39%, according to findings from a report from the American Cancer Society. This decrease translates to well over a quarter of a million averted breast cancer deaths in the United States.
In France and other countries with low to moderate incidence of melanoma, a new study has proposed recommending genetic testing using the rule of 3—screening those with 3 or more primary melanomas or genetically related cancers—instead of the rule of 2.
Cabozantinib reduced the risk for disease progression or death by 52% compared with sunitinib in patients with previously untreated advanced renal cell carcinoma, according to updated results from the CABOSUN trial.
Treatment with pazopanib 600 mg had no benefit over placebo for patients who had undergone nephrectomy for localized or locally advanced renal cell carcinoma.
Treatment with adjuvant chemotherapy improved the overall survival of locally advanced gastroesophageal adenocarcinoma in patients treated with preoperative chemoradiotherapy and resection, according to the results of an analysis of the National Cancer Database.
Use of unilateral intensity-modulated radiotherapy reduced acute toxicities and maintained oncologic outcomes compared with bilateral IMRT in patients with lateralized palatine tonsillar cancer, according to the results of a new study.